Gagan Fervaha1, Ofer Agid2, Hiroyoshi Takeuchi3, Jimmy Lee3, George Foussias2, Konstantine K Zakzanis4, Ariel Graff-Guerrero2, Gary Remington2. 1. Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada. Electronic address: gagan.fervaha@utoronto.ca. 2. Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada; Institute of Medical Science, University of Toronto, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. 3. Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. 4. Department of Psychology, University of Toronto at Scarborough, Scarborough, Canada.
Abstract
BACKGROUND: Movement disorders are common in individuals with schizophrenia, even in those who are not exposed to antipsychotic medications. Extrapyramidal symptoms (EPS) are among the most common abnormal movements in schizophrenia, but their relationship with other features of the illness such as cognition is not well characterized. METHODS: Three hundred and twenty-five individuals with schizophrenia who were not receiving any antipsychotic or anticholinergic medication and participated in the baseline visit of the Clinical Antipsychotic Treatment of Intervention Effectiveness study were included in the present study. EPSs were assessed using the Simpson-Angus Scale, while cognition was measured with a comprehensive neuropsychological test battery. The relationship between EPS and cognitive test performance was evaluated both dimensionally and categorically. RESULTS: Greater severity of EPS was significantly associated with worse cognitive test performance evaluated using a composite score. Eighty-six patients were identified as having parkinsonism and these patients performed worse on cognitive tests than non-parkinsonian patients. These findings remained significant even after accounting for other variables such as severity of psychopathology, sedation, akathisia and dyskinesia. CONCLUSIONS: The present results demonstrate that severity of EPS is reliably linked with poorer scores on tests of cognition. While this may reflect a common pathophysiology underlying neuromotor and neurocognitive deficits, it may also be the case that parkinsonian symptoms such as rigidity and bradykinesia impede test taking ability. Regardless of mechanism, inferences regarding cognitive impairment should take into account the presence of EPS, as well as other variables that may mediate cognitive test findings.
BACKGROUND:Movement disorders are common in individuals with schizophrenia, even in those who are not exposed to antipsychotic medications. Extrapyramidal symptoms (EPS) are among the most common abnormal movements in schizophrenia, but their relationship with other features of the illness such as cognition is not well characterized. METHODS: Three hundred and twenty-five individuals with schizophrenia who were not receiving any antipsychotic or anticholinergic medication and participated in the baseline visit of the Clinical Antipsychotic Treatment of Intervention Effectiveness study were included in the present study. EPSs were assessed using the Simpson-Angus Scale, while cognition was measured with a comprehensive neuropsychological test battery. The relationship between EPS and cognitive test performance was evaluated both dimensionally and categorically. RESULTS: Greater severity of EPS was significantly associated with worse cognitive test performance evaluated using a composite score. Eighty-six patients were identified as having parkinsonism and these patients performed worse on cognitive tests than non-parkinsonianpatients. These findings remained significant even after accounting for other variables such as severity of psychopathology, sedation, akathisia and dyskinesia. CONCLUSIONS: The present results demonstrate that severity of EPS is reliably linked with poorer scores on tests of cognition. While this may reflect a common pathophysiology underlying neuromotor and neurocognitive deficits, it may also be the case that parkinsonian symptoms such as rigidity and bradykinesia impede test taking ability. Regardless of mechanism, inferences regarding cognitive impairment should take into account the presence of EPS, as well as other variables that may mediate cognitive test findings.
Authors: Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett Journal: Am J Med Genet A Date: 2018-05-19 Impact factor: 2.802
Authors: Juan L Molina; Gabriela González Alemán; Néstor Florenzano; Eduardo Padilla; María Calvó; Gonzalo Guerrero; Danielle Kamis; Lee Stratton; Juan Toranzo; Beatriz Molina Rangeon; Helena Hernández Cuervo; Mercedes Bourdieu; Manuel Sedó; Sergio Strejilevich; Claude Robert Cloninger; Javier I Escobar; Gabriel A de Erausquin Journal: Schizophr Bull Date: 2016-03-18 Impact factor: 9.306
Authors: Fernanda F Peres; Raquel Levin; Mayra A Suiama; Mariana C Diana; Douglas A Gouvêa; Valéria Almeida; Camila M Santos; Lisandro Lungato; Antônio W Zuardi; Jaime E C Hallak; José A Crippa; D'Almeida Vânia; Regina H Silva; Vanessa C Abílio Journal: Front Pharmacol Date: 2016-09-28 Impact factor: 5.810
Authors: Juan L Molina; María Calvó; Eduardo Padilla; Mara Balda; Gabriela González Alemán; Néstor V Florenzano; Gonzalo Guerrero; Danielle Kamis; Beatriz Molina Rangeon; Mercedes Bourdieu; Sergio A Strejilevich; Horacio A Conesa; Javier I Escobar; Igor Zwir; C Robert Cloninger; Gabriel A de Erausquin Journal: NPJ Schizophr Date: 2017-01-11
Authors: Erik Boot; Thierry Q Mentzel; Lisa D Palmer; Peter N van Harten; Connie Marras; Anthony E Lang; Anne S Bassett Journal: Mov Disord Date: 2020-05-09 Impact factor: 10.338
Authors: Paulina Cieślik; Monika Woźniak; Jerri M Rook; Mohammed N Tantawy; P Jeffrey Conn; Francine Acher; Krzysztof Tokarski; Magdalena Kusek; Andrzej Pilc; Joanna M Wierońska Journal: Psychopharmacology (Berl) Date: 2018-07-27 Impact factor: 4.530
Authors: Stephan T Egger; Julio Bobes; Katrin Rauen; Erich Seifritz; Stefan Vetter; Daniel Schuepbach Journal: Front Psychiatry Date: 2021-06-25 Impact factor: 4.157